卫光生物 (002880)
SHENZHEN WEIGUANG BIOLOGICAL PRODUCTS Co.,Ltd
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 22680.00
- Circulating A-Shares(W): 22601.30
- Earnings Per Share(RMB): 0.6960
- Net Assets Per Share(RMB): 10.2466
- Operating Revenue(W RMB): 79089.91
- Total Profit(W RMB): 18411.84
- Net Profit Attributable to Parent(W RMB): 15786.05
- Net Profit Growth Rate(%): -13.60
- Weighted Return on Equity(%): 6.9700
- Operating Cash Flow Per Share(RMB): 0.4020
- Undistributed Profit Per Share(RMB): 5.9040
- Capital Reserve Per Share(RMB): 2.4845
2. Main Business
The main business covers:
- Research, development, production and sales of blood products
3. Company Basic Information
- Company Name: Shenzhen Weiguang Biological Products Co., Ltd.
- Listing Date: 2017-06-16
- Industry: Pharmaceutical Manufacturing
- Address: No. 3402, Guangqiao Avenue, Guangming Street, Guangming District, Shenzhen City, Guangdong Province
- Website: www.szwg.com
- Company Profile: The company's predecessor was Shenzhen Weiwu Guangming Biological Products Factory. It completed corporate restructuring in 2001 and established Shenzhen Weiwu Guangming Biological Products Co., Ltd. The company is mainly engaged in the research, development, production and sales of blood products.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shenzhen Guangming District State-owned Assets Supervision and Administration Bureau | General Legal Person | 14798.70 | 65.48 |
| 2 | Wuhan Institute of Biological Products Co., Ltd. | General Legal Person | 1644.30 | 7.28 |
| 3 | Guangzhou Jiahe Biotechnology Co., Ltd. | General Legal Person | 513.37 | 2.27 |
| 4 | Shenzhen Weiguang Biological Products Co., Ltd. - Phase III Employee Stock Ownership Plan | Asset Management Plan | 78.70 | 0.35 |
| 5 | Hong Kong Securities Clearing Company Ltd. | Northbound Funds | 67.94 | 0.30 |
5. Concept Sectors
- Biological Vaccine
- Hepatitis Concept
- Innovative Drug
- Synthetic Biology
- High-Performance Stock
- Private Placement Plan
- Inactive Stock
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information